Article

Therapeutic response in musculoskeletal soft tissue sarcomas: Evaluation by MRI

Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.
NMR in Biomedicine (Impact Factor: 3.04). 07/2011; 24(6):750-63. DOI: 10.1002/nbm.1731
Source: PubMed

ABSTRACT

This article provides a literature review of the use of MRI in monitoring the treatment response of soft tissue sarcomas. The basic classification and physiology of soft tissue tumors are introduced. Then, the major treatment options for soft tissue sarcomas are summarized with brief coverage of possible responses and grading systems. Four major branches of MRI techniques are covered, including conventional T(1) - and T(2) -weighted imaging, contrast-enhanced MRI, MR diffusion and perfusion imaging, and MRS, with a focus on the tumor microenvironment. Although this literature survey focuses on recent clinical developments using these MRI techniques, research venues in preclinical studies, as well as in potential applications other than soft tissue sarcomas, are also included when comparable and/or mutually supporting. Examples from other less-discussed MRI modalities are also briefly covered, not only to complement, but also to expand, the scope and depth of information for various kinds of lesions.

Download full-text

Full-text

Available from: Xin Wang, Mar 30, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of our study was to determine the feasibility and value of proton MR spectroscopy at 3 T for characterizing musculoskeletal tumors. At 3 T, 18 patients with musculoskeletal lesions (four histologically proven to be malignant, 14 proven benign histologically or at clinical follow-up) underwent 23 MR spectroscopy studies, 20 with a single-voxel technique and three with a multivoxel technique. Seventeen patients were imaged with a surface coil and six with a body coil. Choline signal (3.2 ppm) was measured in each voxel and expressed relative to background noise as signal-to-noise ratio (SNR). Choline SNRs of malignant tumors and benign lesions were compared. Diagnostic spectra were obtained in 20 of 23 lesions. For malignant lesions (osteosarcoma with two MR spectroscopy sites, metastasis, grade 1 sarcoma), choline SNRs were 5.2 and 4.2 (performed with body coil) and 4.8 and 18.7 (performed with surface coil), respectively. For benign lesions (neurofibroma, two stress reactions, bone cyst, hemangioma, lipoma, Baker cyst), choline SNR was 6.3 (with surface coil), 5.5 (with surface coil), and not detected for five cases. Seven postoperative patients with myocutaneous flaps showed either the typical spectrum of muscle or negligible choline. Only a water peak existed in a bone cyst and a significant lipid peak in a lipoma. Choline SNRs were different for malignant and benign lesions (11.7 vs 2.3, p = 0.04, as performed with a surface coil). At 3 T, both single-voxel and multivoxel MR spectroscopy are feasible. Proton MR spectroscopy is a potential noninvasive tool for characterizing lesion composition and malignant activity.
    Preview · Article · Jul 2007 · American Journal of Roentgenology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With integrated whole-body PET/MRI, a novel metabolic-anatomic imaging technique recently has been introduced into clinical practice. This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. If PET/MRI literature is not yet available for some types of tumors, potential indications are based on available PET/CT and MRI data. PET/MRI seems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas. With regard to N-staging, PET/MRI can be considered similarly accurate to PET/CT when applied as a whole-body staging approach. M-staging will benefit from MRI accuracy in the brain, the liver, and bone.
    Preview · Article · Jul 2012 · Journal of Nuclear Medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim of this study was to develop a full automatic method for the soft tissue sarcoma (STS) identification and its evaluation during chemotherapy (CT) treatment, based on diffusion MRI. This procedure includes two main phases, the first one is a registration step in order to compose a coregistered set of images concerning morphological and functional images pre and post CT, registered to the pre-treatment T1. The second phase is a fuzzy characterization of STS diffusive parameter along with a fuzzy inference step for the evaluation of treatment response on the characterized area. The results of this procedure are two membership degree maps which measure the probability for each segmented pixel to be responding or not to CT. These two maps could assist radiologists during follow-up assessment, by automatically extracting the lesion volume, report lesion composition, and measure the uncertainty of the estimate, in order to manage the intrinsic and well-known heterogeneity of STS. Many studies demonstrated the prognostic values of diffusion MRI and the apparent diffusion coefficient (ADC) in the assessment of cellularity changes during therapy and their correlation with lesion response. In this scenario, the proposed framework, allows for a total unsupervised identification and probabilistic evaluation of STS treatment response based on diffusion MRI, mapping the local changes of ADC during therapy rather than describe the whole lesion by a statistical moment.
    Full-text · Article · Jan 2014 · IFMBE proceedings
Show more